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Introduction
Alström syndrome is a rare autosomal recessive 
disorder first described in 1959 (1). A wide range of clinical
variability is observed among individuals with Alström
syndrome, including among siblings. The major clinical 
features of Alström syndrome are cone-rod dystrophy 
resulting in childhood blindness; truncal obesity that 
manifests during the first year of life; insulin-resistant type 2
diabetes mellitus (T2DM); progressive sensorineural hearing
loss; and infantile- or adolescent-onset dilated cardiomyopathy
(2). The total number of reported cases of Alström 
syndrome is approximately 300. The gene mutated in 
Alström syndrome patients, ALMS1, has recently been 
identified (3,4). The diagnosis of Alström syndrome is very
difficult in early ages, since the typical morphological 
stigmata become evident only after the age of 6-8 years.
The clinical diagnosis of metabolic syndrome is based 
on the presence of an abnormal glucose metabolism, 
hypertension, hyperlipidemia and obesity (5). The lipid 
profiles of patients with metabolic syndrome are often 
characterized by hypertriglyceridaemia and high LDL 
cholesterol, and low HDL cholesterol. Patients with these
abnormalities have an increased risk of premature coronary
artery disease (6). We report a 7-year-old girl with Alström
syndrome presenting with the features of metabolic 
syndrome in the pediatric age group. 
Case Report
A 7-year-old female was admitted to our department 
due to obesity. The second child of consanguineous 
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birth weight of 3000 g. No problems were observed during
the neonatal period. She was reported to have no mental
retardation or any signs of motor delay.
The patient weighed 32 kg (>95th percentile), her height
was 118.5 centimeters (25-50th percentile) and head 
circumference was 49.5 centimeters (25th percentile). Body
mass index was calculated as 23 kg/m
2 (>95th
percentile).  Systolic and diastolic blood pressure values
were measured as 110 mmHg and 80 mmHg, respectively.
Acanthosis nigricans was noted in the axillary region and
fingers, bilaterally (Figure 1). She had photophobia, and 
cone-rod dystrophy was detected by fundoscopic examination.
Routine investigations, including complete blood count,
liver function tests, renal function tests and sedimentation
rate were within normal ranges. Metabolic screening and
thyroid function tests were normal. Cushing’s syndrome
was excluded by dexamethasone suppression tests. 
Following oral administration of glucose (1.75 g glucose/kg),
blood glucose and plasma insulin levels were 159 mg/dL
and 152.86 mU/ml at 30 min, and 145 mg/dL and 58.97
mU/mL at 120 min, respectively (Table 1). HbA1c was
6.6%. The patient was hyperlipidemic with a total cholesterol
level of 238 mg/dL and a LDL cholesterol level of 163
mg/dL. HDL cholesterol level was low (33 mg/dL). Blood
uric acid level was 5 mg/dL. After metformin treatment (850
mg/day) for 6 months, the oral glucose tolerance test 
showed improved glucose and insulin levels (Table 1). 
Karyotype analysis with standard techniques revealed a
46,XX  karyotype. The patient was diagnosed as a case of
Alström syndrome clinically. Her total genomic DNA 
isolated from peripheral blood leukocytes was analyzed at
Jackson Laboratory (Bar Harbor, ME; GB. Collin and PM.
Nishina). A cytogenetic study was performed on the 
peripheral blood lymphocytes of the patient using high 
resolution and conventional banded-chromosome analysis
including a molecular analysis of ALMS1 gene (GeneBank
accession number AJ417593). As most of the reported 
mutations are harbored within exons 10 and 16, these two
exons were analyzed. A silent polymorphism was detected
at position 8506 (G>T  E>X), a finding consistent with the
clinical diagnosis of Alström syndrome.  
Discussion
In childhood, most individuals with Alström syndrome
have hyperinsulinemia and associated acanthosis nigricans,
hypertriglyceridemia, accelerated skeletal maturity 
(resulting in short adult stature), scoliosis or kyphosis, and
low growth hormone levels. With increasing age, affected
individuals may develop T2DM, other metabolic disturbances,
and renal failure (2). The diabetes mellitus in Alström
syndrome is the result of tissue resistance to the actions of
insulin, as demonstrated by elevated plasma insulin 
levels and glucose intolerance, findings often present 
in childhood. In the literature, diabetes was diagnosed 
between 15 and 25 years of age in the majority of patients,
with hyperinsulinemia often preceding the diabetes (7). 
Our patient with Alström syndrome showed symptoms
of metabolic syndrome including obesity, dyslipidaemia and
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Table 1. Oral glucose tolerance test results and plasma lipid levels before and after metformin treatment
At admission After metformin treatment
Age (years) 7 7.5
Body mass index (kg/m
2)2 3 2 2
Systolic blood pressure (mm/Hg) 110 110
Diastolic blood pressure(mm/Hg) 80 80
Total cholesterol (mg/dL) 238 187
Triglycerides (mg/dL) 138 128
HDL cholesterol (mg/dL) 33 38
LDL cholesterol (mg/dL) 163 136
HOMA-IR 1.72 1.45
Fasting glucose (mg/dL) 91 88
Fasting insulin (mU/mL) 7.69 6.7
120 min glucose (mg/dL) 145 112
120 min insulin (mU/mL) 58.97 25.7
Figure 1. ( (a a) ) Facial appearance of
the patient with truncal obesity,
( (b b) )    Dark shiny patches (acanthosis
nigricans) on fingersglucose intolerance at age 7 years. Currently, there is no 
reported evidence of excessive atherosclerotic disease and
premature coronary artery disease in Alström syndrome 
patients. However, in a recent report, 4 of 22 of Alström
syndrome patients were reported to have succumbed to
cardiac causes at 26 days, 2 years, 6 years, and 19 years of
age. In addition to features of Alström syndrome, the 
metabolic syndrome may lead to complications, such as
hypertension, hypertriglyceridemia, hyperuricemia, 
hyperfibrinogenemia, and impaired glucose tolerance 
or diabetes, which are all risk factors for premature 
atherosclerotic disease (8). In conclusion, increased 
vascular risk is a late complication to be added to the other
typical features of Alström syndrome, as suggested for 
Bardet-Biedl syndrome and Cohen syndrome (9,10). 
In our patient, blood pressure measurements were not
above the 95th percentile for age and height on two 
separate measurements. However, she had high lipid levels
at an early age. Her lipid pattern reflected the typical 
dyslipidaemia (high triglycerides and total cholesterol levels)
observed in overweight individuals. Despite normal fasting
plasma glucose and insulin levels, the 2 hour plasma 
glucose concentration during an oral glucose tolerance test
showed glucose intolerance with marked hyperinsulinemia.
Treatment with metformin and lifestyle changes, including
body weight control with diet modification, were 
recommended. After six months, the treatment proved to
be effective in reducing insulin and lipid levels and in 
ameliorating the complications of metabolic syndrome. 
Alström syndrome may be particularly difficult to 
diagnose because it is rare and because it has a complex
phenotype that evolves over time with multiple possible
presentations. Our patient is another example demonstrating
that diabetes or metabolic syndrome may occur in Alström
syndrome in the early stages of life, and that obese children
with Alström syndrome should be evaluated for metabolic
syndrome. Insulin-resistant children at a younger age who
can compensate by hyperinsulinemia may escape diabetes,
but are still prone to other complications. Without an oral
glucose tolerance test, fasting glucose and insulin 
measurements may fail to identify metabolic syndrome risk
in children with Alström syndrome. It can also be concluded
that metformin can exert some effect on hyperinsulinemia,
impaired glucose tolerance, dyslipidemia and other 
metabolic disturbances in patients with Alström syndrome.
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